|
|
330 Nevada Street
Newton
MA
02460
United States
617-928-0820
|
|
Private
|
Matritech is using its patented proteomics technology to develop diagnostics for the detection of a variety of cancers. The Company’s first two products, the NMP22® Test Kit and NMP22® BladderChek® Test, have been approved for both the monitoring and diagnosis of bladder cancer. The NMP22 products are based on Matritech’s proprietary nuclear matrix protein (NMP) technology, exclusively licensed from the Massachusetts Institute of Technology, which correlates levels of NMPs in body fluids to the presence of cancer. The Company has discovered other proteins associated with bladder, cervical, breast, prostate and colon cancer and is, with its own research staff and through strategic alliances, in various stages of development currently targeted to each of these applications.
|
|
http://www.matritech.com/
|
|
|
|
|
|
|
|
|
|
|
NMP22® BladderChek® Test Product Literature
The NMP22® BladderChek® Test is the only in-office test approved by the FDA for the diagnosis of bladder cancer. The NMP22 BladderChek Test is a painless and non-invasive assay, performed on a single urine sample, that detects elevated levels of NMP22 protein. Healthy individuals generally have very small amounts of NMP22 protein in the urine. However, the level of NMP22 protein is often elevated in the urine of patients with bladder cancer, even at early stages of the disease. The test can be p
read more...
|
|
|
|
|
|
|